Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $20.4 million.

  • Centessa Pharmaceuticals' Accumulated Expenses rose 778.36% to $20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 778.36%. This contributed to the annual value of $50.9 million for FY2024, which is 8445.77% up from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Accumulated Expenses stood at $20.4 million for Q3 2025, which was up 778.36% from $24.0 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' Accumulated Expenses' 5-year high stood at $50.9 million during Q4 2024, with a 5-year trough of $15.3 million in Q1 2023.
  • For the 4-year period, Centessa Pharmaceuticals' Accumulated Expenses averaged around $24.1 million, with its median value being $22.8 million (2023).
  • In the last 5 years, Centessa Pharmaceuticals' Accumulated Expenses plummeted by 2529.63% in 2023 and then skyrocketed by 8445.77% in 2024.
  • Centessa Pharmaceuticals' Accumulated Expenses (Quarter) stood at $24.5 million in 2022, then rose by 12.52% to $27.6 million in 2023, then surged by 84.46% to $50.9 million in 2024, then plummeted by 59.81% to $20.4 million in 2025.
  • Its Accumulated Expenses stands at $20.4 million for Q3 2025, versus $24.0 million for Q2 2025 and $19.1 million for Q1 2025.